Skip navigation
Agenda

Moving Beyond Theory — Strategic and Tactical Decisions for Long-Term Success

January 23-24, 2018
  • Alexandria, VA

Agenda

Want more agenda details? Download the brochure.

DAY ONE Tuesday, January 23, 2018

7:30

Conference Registration and Continental Breakfast

8:30

Chairperson’s Welcome and Opening Remarks

Molly Burich
Associate Director, Public Policy
Boehringer Ingelheim

Year in Review — Lessons Learned
and Strategic Steps Forward

8:45

TIME CAPSULE REVEAL Unpack 2017 Biosimilars Predictions and Discuss Potential Implications for 2018

Anna Rose Welch
Chief Editor, Biosimilar Development
Life Science Connect

Eric R. Sjogren, MS, MBA, RPh
Director, Strategic Business Intelligence
Merck

9:30

MULTI-STAKEHOLDER PANEL Views from the Trenches — Navigating Challenges and Opportunities for Biosimilars

MODERATOR:

Molly Burich
Associate Director, Public Policy
Boehringer Ingelheim

PANELISTS:

Edric Engert
Managing Director
Abraxeolus Consulting

Lawrence A. (Larry) LaMotte
Vice President, Public Policy, Immune Deficiency Foundation and Representative
Patients for Biologics Safety and Access (PBSA)

TJ Garrigan
Senior Director, Policy
Association for Accessible Medicines

10:30

Networking and Refreshment Break

11:00

Increase Biosimilar Antibody Portfolio Value with Adapter CAR™

Ronald Dudek
Director, Adapter CAR Program Manager
Lentigen Technology, Inc.

Navigate the Increasingly Active
and Evolving Regulatory Landscape

11:45

Considerations in Demonstrating Interchangeability with a Reference Product — Clarifying FDA’s Draft Guidance

Bruce Leicher
Senior Vice President, General Counsel
Momenta Pharmaceuticals

12:45

Networking Luncheon and Interactive Discussions

Join one of three discussion topics for an interactive, networking lunch experience. Identify industry counterparts with similar responsibilities and interests and get the conversation started surrounding key challenges for bio/pharmaceutical companies operating within the biosimilar landscape.

I. Biosimilar Product Reimbursement and Pricing

II. U.S. Biosimilar Regulatory Updates and Legal Implications

III. Biosimilar Market Access and Commercialization

2:15

LEGAL SPOTLIGHT Explore Unresolved Questions from Sandoz v. Amgen SCOTUS Ruling

Lisa B. Pensabene
Partner
O'Melveny & Myers LLP

3:00

Networking and Refreshment Break

Pricing, Reimbursement and Product Uptake

3:30

CASE STUDY Overcome Reimbursement Hurdles in an Expanding U.S. Biosimilars Market

Nicholas Simmons-Stern
Senior Consultant
Trinity Partners, LLC

John Greenaway
Principal
Trinity Partners, LLC

4:15

Commercial Considerations and Market Access Updates for
US Biosimilars in the US 2017

Joseph P. Fuhr, Jr.
Professor Emeritus of Economics
Widener University

5:00

Close of Day One

Networking, Wine and Cheese Reception immediately following the final session on day one

DAY TWO Wednesday, January 24, 2018

8:00

Continental Breakfast

8:30

Chairperson’s Review of Day One

Molly Burich
Associate Director, Public Policy
Boehringer Ingelheim

8:45

PAYER PERSPECTIVE TOWN HALL Practical Insights to Improve Product Uptake and Encourage Biosimilar Adoption

Edric Engert
Managing Director
Abraxeolus Consulting

Sheila Arquette
Executive Director, National Association of Specialty Pharmacy (NASP);
Strategic Pharmacy Projects Advisor, Independent Health

9:45

Play the Name Game — Recommendations for Implementing the FDA’s Biologic Naming Policy

Thomas Felix, M.D.
Medical Director, R&D Policy, Intercontinental Region
Amgen

10:30

Networking and Refreshment Break

Commercial Strategy and Market Access Playbook

11:00

Biosimilar Commercialization Strategies — Supportive and Therapeutic Care

Pete Perron
Vice President and General Manager, GPO Services
McKesson Specialty Health

Omar Hafez
Vice President, Multisource Products, Analytics
McKesson Specialty Health

11:45

Networking Luncheon

1:00

EMPLOYER VOICE A Focus on Employers —
What Is the Opportunity for Employers to Realize Savings from Biosimilars?

Tiffany McCaslin
Senior Policy Analyst, Public Policy
National Business Group on Health

Tom Keonig
Executive Director, Market Access, Biosimilars
Boehringer Ingelheim

1:45

Optimize Distribution Strategy and Reimbursement for Biosimilars

James Van Lieshout
Pharmaceutical Industry Consultant
Self-Employed

2:30

Chairperson’s Closing Remarks and Q&A

Molly Burich
Associate Director, Public Policy
Boehringer Ingelheim

3:00

Close of Conference

Agenda

Want more agenda details? Download the brochure.
Want more agenda details? Download the brochure.

DAY ONE Tuesday, January 23, 2018

7:30

Conference Registration and Continental Breakfast

8:30

Chairperson’s Welcome and Opening Remarks

Molly Burich
Associate Director, Public Policy
Boehringer Ingelheim

Year in Review — Lessons Learned
and Strategic Steps Forward

8:45

TIME CAPSULE REVEAL Unpack 2017 Biosimilars Predictions and Discuss Potential Implications for 2018

Anna Rose Welch
Chief Editor, Biosimilar Development
Life Science Connect

Eric R. Sjogren, MS, MBA, RPh
Director, Strategic Business Intelligence
Merck

9:30

MULTI-STAKEHOLDER PANEL Views from the Trenches — Navigating Challenges and Opportunities for Biosimilars

MODERATOR:

Molly Burich
Associate Director, Public Policy
Boehringer Ingelheim

PANELISTS:

Edric Engert
Managing Director
Abraxeolus Consulting

Lawrence A. (Larry) LaMotte
Vice President, Public Policy, Immune Deficiency Foundation and Representative
Patients for Biologics Safety and Access (PBSA)

TJ Garrigan
Senior Director, Policy
Association for Accessible Medicines

10:30

Networking and Refreshment Break

11:00

Increase Biosimilar Antibody Portfolio Value with Adapter CAR™

Ronald Dudek
Director, Adapter CAR Program Manager
Lentigen Technology, Inc.

Navigate the Increasingly Active
and Evolving Regulatory Landscape

11:45

Considerations in Demonstrating Interchangeability with a Reference Product — Clarifying FDA’s Draft Guidance

Bruce Leicher
Senior Vice President, General Counsel
Momenta Pharmaceuticals

12:45

Networking Luncheon and Interactive Discussions

Join one of three discussion topics for an interactive, networking lunch experience. Identify industry counterparts with similar responsibilities and interests and get the conversation started surrounding key challenges for bio/pharmaceutical companies operating within the biosimilar landscape.

I. Biosimilar Product Reimbursement and Pricing

II. U.S. Biosimilar Regulatory Updates and Legal Implications

III. Biosimilar Market Access and Commercialization

2:15

LEGAL SPOTLIGHT Explore Unresolved Questions from Sandoz v. Amgen SCOTUS Ruling

Lisa B. Pensabene
Partner
O'Melveny & Myers LLP

3:00

Networking and Refreshment Break

Pricing, Reimbursement and Product Uptake

3:30

CASE STUDY Overcome Reimbursement Hurdles in an Expanding U.S. Biosimilars Market

Nicholas Simmons-Stern
Senior Consultant
Trinity Partners, LLC

John Greenaway
Principal
Trinity Partners, LLC

4:15

Commercial Considerations and Market Access Updates for
US Biosimilars in the US 2017

Joseph P. Fuhr, Jr.
Professor Emeritus of Economics
Widener University

5:00

Close of Day One

Networking, Wine and Cheese Reception immediately following the final session on day one

DAY TWO Wednesday, January 24, 2018

8:00

Continental Breakfast

8:30

Chairperson’s Review of Day One

Molly Burich
Associate Director, Public Policy
Boehringer Ingelheim

8:45

PAYER PERSPECTIVE TOWN HALL Practical Insights to Improve Product Uptake and Encourage Biosimilar Adoption

Edric Engert
Managing Director
Abraxeolus Consulting

Sheila Arquette
Executive Director, National Association of Specialty Pharmacy (NASP);
Strategic Pharmacy Projects Advisor, Independent Health

9:45

Play the Name Game — Recommendations for Implementing the FDA’s Biologic Naming Policy

Thomas Felix, M.D.
Medical Director, R&D Policy, Intercontinental Region
Amgen

10:30

Networking and Refreshment Break

Commercial Strategy and Market Access Playbook

11:00

Biosimilar Commercialization Strategies — Supportive and Therapeutic Care

Pete Perron
Vice President and General Manager, GPO Services
McKesson Specialty Health

Omar Hafez
Vice President, Multisource Products, Analytics
McKesson Specialty Health

11:45

Networking Luncheon

1:00

EMPLOYER VOICE A Focus on Employers —
What Is the Opportunity for Employers to Realize Savings from Biosimilars?

Tiffany McCaslin
Senior Policy Analyst, Public Policy
National Business Group on Health

Tom Keonig
Executive Director, Market Access, Biosimilars
Boehringer Ingelheim

1:45

Optimize Distribution Strategy and Reimbursement for Biosimilars

James Van Lieshout
Pharmaceutical Industry Consultant
Self-Employed

2:30

Chairperson’s Closing Remarks and Q&A

Molly Burich
Associate Director, Public Policy
Boehringer Ingelheim

3:00

Close of Conference